{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T13:02:55Z","timestamp":1779714175526,"version":"3.53.1"},"reference-count":31,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: Radiotherapy (RT) is effective for cutaneous T-cell lymphoma (CTCL), but the optimal focal dose remains debated. We evaluated lesion response, local control, toxicity and patient satisfaction after 2 \u00d7 4 Gy compared with higher-dose regimens.Patient\/material and methods: This single-centre retrospective study included CTCL patients treated with RT between 1990 and 2019 at a German university hospital. Lesions receiving 2 \u00d7 4 Gy (low-dose) were compared with lesions treated with higher doses (median 34 Gy). Endpoints were complete response (CR), overall response (OR), 1- and 5-year local control rate (LCR; Kaplan\u2013Meier\/log-rank), in-field relapse and toxicity (common terminology criteria for adverse events\/ Radiation Therapy Oncology Group (RTOG)-European Organisation for Research and Treatment of Cancer). Patient satisfaction Freiburg Index of Patient Satisfaction (FIPS) was assessed in a subsample.Results: Thirty-two patients with 227 lesions were analysed (195 low-dose; 32 higher-dose). CR was achieved in 88.2% vs 90.6% and OR in 94.4% vs 100%, respectively (low- vs higher-dose). LCR was inferior after low-dose RT, with 1- and 5-year LCR estimates of 82 and 67% versus 100 and 96% after higher-dose RT (log-rank p = 0.013). In-field relapse occurred in 20.1% (37\/184) vs 3.6% (1\/28) of lesions with follow-up (Fisher p = 0.034). No toxicity &gt;\u2009grade 2 was observed, and did not differ between groups (p = 0.695 and p = 0.657). In 11 FIPS questionnaires, satisfaction was high (mean score 1.27; median 1).Interpretation: Low-dose 2 \u00d7 4 Gy yields excellent initial response with minimal toxicity, but inferior local control compared with higher-dose focal RT. Findings support intent-based dosing: 2 \u00d7 4 Gy for symptom-driven treatment with re-irradiation as a pragmatic option, and higher-dose RT when durable local control is the primary objective.<\/jats:p>","DOI":"10.2340\/1651-226x.2026.45728","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T12:17:45Z","timestamp":1779711465000},"page":"468-475","source":"Crossref","is-referenced-by-count":0,"title":["Dose-de-escalated focal radiotherapy for primary cutaneous T-cell lymphoma: a lesion-based retrospective cohort study"],"prefix":"10.2340","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2813-1331","authenticated-orcid":false,"given":"Philipp","family":"Linde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Rosenbrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ferdinandus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Fokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Baues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"156524","doi-asserted-by":"crossref","unstructured":"Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Bernreiter S, Cozzio A, et al. S2k-Leitlinie \u2013 Kutane Lymphome (ICD10 C82-C86): update 2021. J Dtsch Dermatol Ges. 2022;20(4):537\u201355.","DOI":"10.1111\/ddg.14706_g"},{"key":"156525","doi-asserted-by":"crossref","unstructured":"Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703\u201314.","DOI":"10.1182\/blood-2018-11-881268"},{"key":"156526","doi-asserted-by":"crossref","unstructured":"Erratum in: Blood. 2019;134(13):1112.","DOI":"10.1182\/blood-2019-130559"},{"key":"156527","doi-asserted-by":"crossref","unstructured":"Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, et al. NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020. J Natl Compr Canc Netw. 2020;18(5):522\u201336.","DOI":"10.6004\/jnccn.2020.0022"},{"key":"156528","doi-asserted-by":"crossref","unstructured":"Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova E, et al. EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 update 2023. Eur J Cancer. 2023;195:113343.","DOI":"10.1016\/j.ejca.2023.113343"},{"key":"156529","doi-asserted-by":"crossref","unstructured":"Elsayad K, Guenova E, Assaf C, Nicolay JP, Trautinger F, Stadler R, et al. Radiotherapy in cutaneous lymphomas: recommendations from the EORTC cutaneous lymphoma tumour group. Eur J Cancer. 2024;212:115064.","DOI":"10.1016\/j.ejca.2024.115064"},{"key":"156530","doi-asserted-by":"crossref","unstructured":"Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, Noordijk EM. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74(1):154\u20138.","DOI":"10.1016\/j.ijrobp.2008.06.1918"},{"key":"156531","doi-asserted-by":"crossref","unstructured":"Patel AM, West L, Atluri PS, Yi SF, Rizvi S, Geethakumari PR, et al. Optimizing palliative focal radiation therapy dose in cutaneous T-cell lymphoma: how low can you go? Pract Radiat Oncol. 2023;13(2):e192\u20139.","DOI":"10.1016\/j.prro.2022.10.004"},{"key":"156532","doi-asserted-by":"crossref","unstructured":"Yahalom J, Dabaja BS, Ricardi U, Ng A, Mikhaeel NG, Vogelius IR, et al. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood. 2020;135(21):1829\u201332.","DOI":"10.1182\/blood.2020006028"},{"key":"156533","doi-asserted-by":"crossref","unstructured":"Miccio JA, Wilson LD, Kann BH, Jairam V, Beckta J, Foss FM, et al. Cutaneous T-cell lymphoma: trends in radiation doses and patterns of care 2004\u20132015. Anticancer Res. 2019;39(1):253\u20139.","DOI":"10.21873\/anticanres.13105"},{"key":"156534","doi-asserted-by":"crossref","unstructured":"Wang P, Gilbert M, Lim HW, McHargue C, Friedman BJ, Veenstra JJ, et al. Single-fraction radiation therapy for localized cutaneous T-cell lymphoma. Pract Radiat Oncol. 2023;13(4):346\u201350.","DOI":"10.1016\/j.prro.2023.03.015"},{"key":"156535","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"156536","unstructured":"National Cancer Institute (US). Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Bethesda (MD): National Cancer Institute; 2017."},{"key":"156537","unstructured":"National Cancer Institute. Common toxicity criteria (CTC) version 2.0 [Internet]. 1999 [cited 2026 Feb 16]. Available from: https:\/\/www.eortc.be\/services\/doc\/ctc\/"},{"key":"156538","doi-asserted-by":"crossref","unstructured":"Schoenthaler M, Farin E, Karcz WK, Ardelt P, Wetterauer U, Miernik A. Der Freiburger Index f\u00fcr Patientenzufriedenheit. Vorstellung eines neuen Instruments und seiner psychometrischen Eigenschaften [The Freiburg index of patient satisfaction: introduction and validation of a new questionnaire]. Dtsch Med Wochenschr. 2012;137(9):419\u201324. German.","DOI":"10.1055\/s-0031-1298976"},{"key":"156539","doi-asserted-by":"crossref","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","DOI":"10.1001\/jama.2013.281053"},{"key":"156540","doi-asserted-by":"crossref","unstructured":"Hoppe RT. Mycosis fungoides: radiation therapy. Dermatol Ther. 2003;16(4):347\u201354.","DOI":"10.1111\/j.1396-0296.2003.01647.x"},{"key":"156541","doi-asserted-by":"crossref","unstructured":"Mazzeo E, Rubino L, Buglione M, Antognoni P, Magrini SM, Bertoni F, et al. The current management of mycosis fungoides and S\u00e9zary syndrome and the role of radiotherapy: principles and indications. Rep Pract Oncol Radiother. 2013;19(2):77\u201391.","DOI":"10.1016\/j.rpor.2013.07.009"},{"key":"156542","doi-asserted-by":"crossref","unstructured":"Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas \u2013 an update 2021. Hematol Oncol. 2021;39(Suppl 1):46\u201351.","DOI":"10.1002\/hon.2850"},{"key":"156543","doi-asserted-by":"crossref","unstructured":"Oymanns M, Daum-Marzian M, Bellm A, Elsayad K, Eich HT, Assaf C. Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma. Br J Dermatol. 2023;188(1):145\u20136.","DOI":"10.1093\/bjd\/ljac012"},{"key":"156544","doi-asserted-by":"crossref","unstructured":"Rolf D, Elsayad K, Eich HT. Acute and sub-acute toxicity profile of ultra-hypofractionated low-dose total skin electron beam with two 4 Gy fractions for cutaneous T cell lymphoma. J Cancer Res Clin Oncol. 2021;147(6):1757\u201361.","DOI":"10.1007\/s00432-020-03449-7"},{"key":"156545","doi-asserted-by":"crossref","unstructured":"Specht L, Dabaja B, Illidge T, Wilson LD, Hoppe RT, International Lymphoma Radiation Oncology Group. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):32\u20139.","DOI":"10.1016\/j.ijrobp.2015.01.008"},{"key":"156546","doi-asserted-by":"crossref","unstructured":"K\u00f6nig L, H\u00f6rner-Rieber J, Bernhardt D, Hommertgen A, Rieken S, Debus J, et al. Response rates and recurrence patterns after low-dose radiotherapy with 4 Gy in patients with low-grade lymphomas. Strahlenther Onkol. 2018;194(5):454\u201361. English.","DOI":"10.1007\/s00066-018-1277-3"},{"key":"156547","doi-asserted-by":"crossref","unstructured":"Wong R, Jones G, Farrar N, Sur R, Wilson LD. Local superficial radiotherapy (LSRT) for newly diagnosed stage IA patch-plaque mycosis fungoides (MF) with only one, two or three presenting lesions. Int J Radiat Oncol Biol Phys. 2003;57(2):S289\u201390.","DOI":"10.1016\/S0360-3016(03)01145-3"},{"key":"156548","doi-asserted-by":"crossref","unstructured":"Wilson LD, Kacinski BM, Jones GW. Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (Mycosis Fungoides). Int J Radiat Oncol Biol Phys. 1998;40(1):109\u201315.","DOI":"10.1016\/S0360-3016(97)00553-1"},{"key":"156549","doi-asserted-by":"crossref","unstructured":"Sampogna F, Frontani M, Baliva G, Lombardo GA, Alvetreti G, Di Pietro C, et al. Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol. 2009;160(4):815\u201322.","DOI":"10.1111\/j.1365-2133.2008.08992.x"},{"key":"156550","doi-asserted-by":"crossref","unstructured":"Fabian A, R\u00fchle A, Liegl G, Domschikowski J, Trommer M, Ferdinandus S, et al. Quality of life in cancer patients at the end of radiotherapy compared to a general population sample in Germany. Int J Cancer. 2026;158(4):1021\u201330.","DOI":"10.1002\/ijc.70152"},{"key":"156551","doi-asserted-by":"crossref","unstructured":"Dabaja B. Renaissance of low-dose radiotherapy concepts for cutaneous lymphomas. Oncol Res Treat. 2017;40(5):255\u201360.","DOI":"10.1159\/000470845"},{"key":"156552","doi-asserted-by":"crossref","unstructured":"Thomas TO, Agrawal P, Guitart J, Rosen ST, Rademaker AW, Querfeld C, et al. Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2013;85(3):747\u201353.","DOI":"10.1016\/j.ijrobp.2012.05.034"},{"key":"156553","doi-asserted-by":"crossref","unstructured":"Winther AH, Vikstr\u00f6m S, Brauner H. Transformed mycosis fungoides with penile involvement successfully treated with local radiation. Acta Oncol. 2023;62(4):404\u20136.","DOI":"10.1080\/0284186X.2023.2199941"},{"key":"156554","doi-asserted-by":"crossref","unstructured":"Shikama N. Local radiation for cutaneous T-cell lymphoma other than mycosis fungoides and S\u00e9zary syndrome. Chin Clin Oncol. 2019;8(1):8.","DOI":"10.21037\/cco.2018.07.01"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45728\/54063","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45728\/54063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T12:17:53Z","timestamp":1779711473000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/45728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":31,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2026.45728","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}